Carlos Becerra

6.0k citations

98 papers · 2.5k indexed · 1 hit paper · h-index 24

Oncology top 2%
- Colorectal Cancer Treatments and Studies 20
- Pancreatic and Hepatic Oncology Research 16
- Cancer Treatment and Pharmacology 14
- Cancer Immunotherapy and Biomarkers 12
- HER2/EGFR in Cancer Research 10
Cancer Research top 5%
Molecular Biology top 5%
- PI3K/AKT/mTOR signaling in cancer 9
Immunology top 10%
Pathology and Forensic Medicine top 5%
Pulmonary and Respiratory Medicine
- Gastric Cancer Management and Outcomes 9
- Lung Cancer Treatments and Mutations 9

Co-authors: Udit Verma Richard B. Gaynor Eugene P. Frenkel Rama Mohan Surabhi Razelle Kurzrock Howard A. Burris Jeffrey R. Infante Michael S. Gordon
Cited by: Oncology Cancer Research Molecular Biology
Journals: Journal of Clinical Oncology (39 papers)Cancer Chemotherapy and Pharmacology (6 papers)Annals of Oncology (5 papers)
Partner nations: United States Spain Canada

In The Last Decade

Carlos Becerra

92 papers receiving 2.5k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Carlos Becerra

Since Specialization

Citations

This map shows the geographic impact of Carlos Becerra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlos Becerra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlos Becerra more than expected).

Fields of papers citing papers by Carlos Becerra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carlos Becerra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlos Becerra. The network helps show where Carlos Becerra may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Carlos Becerra, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Carlos Becerra Line = papers co-authored together Carlos Becerra links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B Clinical Cancer Research ·Diwakar Davar,Zeynep Eroglu,Mohammed Milhem,Carlos Becerra,Martin Gutierrez,Antoni Ribas,Hsin‐ya Kuo,Kai-Yun Huang,Hailei Zhang,Al Mamun Bhuyan Abdulla,Etwina Gandert,I Perucka,Shyam Srivats,В.П. Мешалкин,Arindam Dhar,Patricia LoRusso	2025	1
2	An open-label, phase 1, multicenter study to evaluate the safety and preliminary anti-tumor activity of NT-112 in human leukocyte antigen-C08:02–positive adult patients with unresectable, advanced, and/or metastatic solid tumors that are positive for the KRAS G12D mutation. Journal of Clinical Oncology* ·Salman R. Punekar,Meredith Pelster,Carlos Becerra,J. Randolph Hecht,Andrew Scott Paulson,Patrick Grierson,Maria Pia Morelli,Rom S. Leidner,Mandana Kamgar,Joaquina Baranda,Syed Mohammad Ali Kazmi,Ardaman Shergill,Anne Robinson,Anuradha Patel,A Hoffmann,Jeroen van Heijst,Nathan Demars,Arianne Perez,Sarah S. Cohen,Marwan Fakih	2024	3
3	A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment Cancer Chemotherapy and Pharmacology ·Muhammad Wasif Saif,Carlos Becerra,Marwan Fakih,Weijing Sun,Lazar Popović,Smitha Krishnamurthi,Thomas J. George,Michelle A. Rudek,Dale R. Shepard,Nuria Suárez,Vladimír Šrámek,Bojan Zarić,Ikuo Yamamiya,Karim A. Benhadji,K Hamada,Yaohua He,Lee S. Rosen	2021	6
4	Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors Cancer Chemotherapy and Pharmacology ·Anthony W. Tolcher,Razelle Kurzrock,V. Valero,René González,Rebecca S. Heist,Antoinette R. Tan,Julie Means‐Powell,Theresa L. Werner,Carlos Becerra,Chenxi Wang,晴啓大谷,Shanker Kalyana‐Sundaram,Joseph F. Kleha,Jennifer Gauvin,Anthony M. D’Amelio,Catherine Ellis,Nageatte Ibrahim,Yan Li	2020	47
5	Open‐label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment British Journal of Clinical Pharmacology ·Muhammad Wasif Saif,Lee S. Rosen,Michelle A. Rudek,Weijing Sun,Dale R. Shepard,Carlos Becerra,G Mugnolo,景彩丽,Robert Winkler	2019	7
6	A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer Breast Cancer Research and Treatment ·Vandana G. Abramson,Mafalda Oliveira,Andrés Cervantes,Hans Wildiers,Manish R. Patel,Todd M. Bauer,Philippe L. Bédard,Carlos Becerra,Stephen Richey,Michael C. Wei,Eric L. Reyner,John H. Bond,Na Cui,Timothy R. Wilson,Heather M. Moore,Cristina Saura,Ian E. Krop	2019	4
7	Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer Clinical Cancer Research ·Raju Kandimalla,Feng Gao,Takatoshi Matsuyama,Toshiaki Ishikawa,Hiroyuki Uetake,Naoki Takahashi,Yasuhide Yamada,Carlos Becerra,Scott Kopetz,Xin Wang,Ajay Goel	2018	33
8	Initial results of a phase 1 dose expansion cohort of M6620 (formerly VX-970), an ATR inhibitor, in combination with cisplatin in patients with advanced triple-negative breast cancer NCT02157792) Annals of Oncology ·Melinda L. Telli,Simon Lord,Emma Dean,Tonghao Pei,H-T. Arkenau,Carlos Becerra,Sara M. Tolaney,Rui Tang,Marina S. Penney,John R. Pollard,Carl Degroote,Scott Z. Fields,Geoffrey I. Shapiro	2017	3
9	Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors Oncology ·Emiliano Calvo,Fadi Braiteh,Daniel D. Von Hoff,Robert R. McWilliams,Carlos Becerra,Matthew D. Galsky,Gayle Jameson,Ji Lin,Scott McKane,Enaksha Wickremsinhe,Scott M. Hynes,Aimee Bence Lin,Karla Hurt,Donald Richards	2016	33
10	A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers Investigational New Drugs ·Andrew L. Coveler,Andrew H. Ko,Daniel V.T. Catenacci,Daniel D. Von Hoff,Carlos Becerra,Nancy Whiting,Jing Yang,Brian M. Wolpin	2016	21
11	A Phase II Study with Cetuximab and Radiation Therapy for Patients with Surgically Resectable Esophageal and GE Junction Carcinomas: Hoosier Oncology Group G05-92 Journal of Thoracic Oncology ·Carlos Becerra,Nasser H. Hanna,Andrea M. McCollum,Dimitar Kostadinov,Robert Timmerman,R Luttik,Kenneth A. Kesler,Menggang Yu,Yan Tong,Hak Choy	2013	14
12	Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trialbreakdown → The Lancet Oncology ·Jeffrey R. Infante,Leslie A. Fecher,Gerald S. Falchook,Sujatha Nallapareddy,Michael S. Gordon,Carlos Becerra,Douglas J. DeMarini,Donna S. Cox,Yanmei Xu,Shannon R. Morris,Vijay Peddareddigari,Ngocdiep T. Le,Lowell L. Hart,Johanna C. Bendell,Gail Eckhardt,Razelle Kurzrock,Keith T. Flaherty,Howard A. Burris,Wells A. Messersmith	2012	424
13	Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer Clinical Cancer Research ·Srinivas Nagaraj,Je-In Youn,Hannah Weber,Cristina Iclozan,Lily Lu,Matthew J. Cotter,Colin J. Meyer,Carlos Becerra,Mayer Fishman,Scott Antonia,Michael B. Sporn,Karen T. Liby,Bhupendra Rawal,Ji‐Hyun Lee,Dmitry I. Gabrilovich	2010	225
14	Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: Results of a Phase II, randomized, noncomparative study Investigational New Drugs ·Donald Richards,최창섭,Carlos Becerra,Lalan S. Wilfong,Robert H. Gersh,Kristi A. Boehm,Zhan Feng,Lina Asmar,Scott P. Myrand,Rebecca R. Hozak,Luping Zhao,John F. Gill,Brian P. Mullaney,Coleman K. Obasaju,Steven J. Nicol	2009	43
15	IκB Kinase α Regulates Subcellular Distribution and Turnover of Cyclin D1 by Phosphorylation Journal of Biological Chemistry ·Youn Tae Kwak,Rui Li,Carlos Becerra,Debu Tripathy,Eugene P. Frenkel,Udit Verma	2005	56
16	Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study International Journal of Cancer ·Carlos Becerra,Eugene P. Frenkel,Raheela Ashfaq,Richard B. Gaynor	2003	50
17	Phase II study of pemetrexed disodium (Alimta®) administered with oral folic acid in patients with advanced gastric cancer Annals of Oncology ·E. Bajetta,Luigi Celio,Roberto Buzzoni,L. Ferrari,Alfonso Marchianò,Antonia Martinetti,R. Longarini,Carlos Becerra,Carl F. Ilardi,Fritz Göttler	2003	49
18	Reversible Renal Toxicity Resulting From High Single Doses of the New Radiosensitizer Gadolinium Texaphyrin American Journal of Clinical Oncology ·David I. Rosenthal,Carlos Becerra,Robert D. Toto,David P. Carbone,Eugene P. Frenkel	2000	15
19	Palmitoyl-Protein thioesterase deficiency in a novel granular variant of LINCL Pediatric Neurology ·Sharada Khanal Ghimire,F. Connell,Wojciech Kaczmarski,Ann Ricksecker,A. N. Siakotos,Carlos Becerra,Sandra L. Hofmann	1998	28
20	Humoral and cellular immune responses to experimental Fasciola hepatica infections in goats Parasitology Research ·Álvaro Martínez‐Moreno,F.J. Martínez-Moreno,I. Acosta,Harisairam Angirekula,Carlos Becerra,Santiago Hernández	1997	27

About Carlos Becerra

Carlos Becerra is a scholar working on Oncology, Toxicology and Cancer Research, having authored 98 papers that have together received 2.5k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (20 papers), Pancreatic and Hepatic Oncology Research (16 papers), Cancer Treatment and Pharmacology (14 papers), Cancer Immunotherapy and Biomarkers (12 papers), HER2/EGFR in Cancer Research (10 papers), PI3K/AKT/mTOR signaling in cancer (9 papers), Gastric Cancer Management and Outcomes (9 papers) and Lung Cancer Treatments and Mutations (9 papers). The work is most often cited by research in Oncology (1.1k citations), Cancer Research (379 citations) and Molecular Biology (1.4k citations). Carlos Becerra has collaborated with scholars based in United States, Spain and Canada. Frequent co-authors include Udit Verma, Richard B. Gaynor, Eugene P. Frenkel, Rama Mohan Surabhi, Razelle Kurzrock, Howard A. Burris, Jeffrey R. Infante, Michael S. Gordon, Donna S. Cox and Keith T. Flaherty. Their work appears in journals such as Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology, Annals of Oncology, Clinical Cancer Research and Investigational New Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact